Markets
What each regulator has published about each compound, market by market.
Every cell names the authority and links the source it came from. A cell reads "Not found" when the search was run in the local language and nothing published names the compound. That is a finding, not a gap we filled with a guess.
| Compound | United Kingdom | Germany | Netherlands | Poland | Sweden |
|---|---|---|---|---|---|
| Semaglutide | Approved medicineMHRA, 2026-06-11 | Approved medicineEMA (centralised authorisation, valid in Germany), 2018-02-08 | Approved medicineCBG-MEB, 2018-05-31 | Approved medicineURPL; EMA (centralised authorisation, valid in Poland), 2024-09-19 | Approved medicineLakemedelsverket, undated |
| BPC-157 | No authorisationUK Anti-Doping, applying the WADA Prohibited List, undated | No authorisationNADA Deutschland, applying the WADA Prohibited List, 2025-12-10 | No authorisationDopingautoriteit, applying the WADA Prohibited List, 2025-12-15 | No authorisationGlowny Inspektorat Farmaceutyczny (GIF), 2024-10-01 | No authorisationAntidoping Sverige, applying the WADA Prohibited List, 2026-01-01 |
| Melanotan II (MT-2) | No authorisationMHRA, 2014-06-16 | No authorisationBfArM, 2010-10-28 | Not foundno source found | Not foundno source found | No authorisationLakemedelsverket, 2010-07-26 |
15 of 1295 cells published. Researched 2026-09-19. A status is the regulator's position on that date, not ours, and not legal advice.
| Tell us the compounds and the market you sell into. | Ask about a market |
Ask about a compound in your market
Tell us the compound and the market. We answer with the regulator's position and the source.